📊 SPRB Key Takeaways
Is Spruce Biosciences, Inc.. (SPRB) a Good Investment?
Spruce Biosciences is a pre-revenue biopharmaceutical company burning significant cash with zero revenue generation and -$12.3M net losses. While strong liquidity ($54.1M cash) provides near-term runway, the company faces severe operational challenges with negative operating cash flow (-$8.7M) and only ~6 quarters of cash runway at current burn rates without visible revenue generation.
Spruce Biosciences, Inc.. Key Strengths (SPRB)
- Exceptional cash position of $54.1M provides runway for clinical development and operations
- Strong liquidity ratios (4.67x current ratio) enable debt service and operational flexibility
- Net loss improved 26.5% YoY, indicating some cost management and progress toward profitability
SPRB Stock Risks: Spruce Biosciences, Inc.. Investment Risks
- Complete revenue collapse (-100% YoY) with zero revenue indicates pre-commercial stage with no approved products
- Significant operating losses (-$12.0M) and negative operating cash flow (-$8.7M) unsustainable without revenue generation
- Limited cash runway of ~6 quarters at current burn rate; company dependent on financing or clinical success
- Biotech sector execution risk with no visible near-term revenue catalysts or approved product portfolio
- Minimal insider activity (1 Form 4 filing in 90 days) signals lack of insider confidence
Key Metrics to Watch
- Operating cash burn rate and cash runway extension/depletion timeline
- Clinical trial progress and FDA milestone achievements for pipeline products
- Revenue generation from approved products or licensing partnerships
Spruce Biosciences, Inc.. (SPRB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.67x current ratio provides a solid financial cushion.
SPRB Profit Margin, ROE & Profitability Analysis
SPRB vs Healthcare Sector: How Spruce Biosciences, Inc.. Compares
How Spruce Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Spruce Biosciences, Inc.. Stock Overvalued? SPRB Valuation Analysis 2026
Based on fundamental analysis, Spruce Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Spruce Biosciences, Inc.. Balance Sheet: SPRB Debt, Cash & Liquidity
SPRB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Spruce Biosciences, Inc..'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-96.40 indicates the company is currently unprofitable.
SPRB Revenue Growth, EPS Growth & YoY Performance
SPRB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$8.2M | $-14.58 |
| Q2 2025 | N/A | -$2.1M | $-3.50 |
| Q1 2025 | N/A | -$11.6M | $-0.28 |
| Q3 2024 | $602.0K | -$8.7M | $-0.21 |
| Q2 2024 | $1.6M | -$9.2M | $-0.22 |
| Q1 2024 | $2.0M | -$11.6M | $-0.28 |
| Q3 2023 | N/A | -$11.4M | $-0.30 |
| Q2 2023 | N/A | -$11.9M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Spruce Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
SPRB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Spruce Biosciences, Inc.. (CIK: 0001683553)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 26, 2026 | 4 | xslF345X06/form4-05262026_040510.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_040508.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_040505.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_040503.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_040512.xml | View → |
❓ Frequently Asked Questions about SPRB
What is the AI rating for SPRB?
Spruce Biosciences, Inc.. (SPRB) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SPRB's key strengths?
Claude: Exceptional cash position of $54.1M provides runway for clinical development and operations. Strong liquidity ratios (4.67x current ratio) enable debt service and operational flexibility.
What are the risks of investing in SPRB?
Claude: Complete revenue collapse (-100% YoY) with zero revenue indicates pre-commercial stage with no approved products. Significant operating losses (-$12.0M) and negative operating cash flow (-$8.7M) unsustainable without revenue generation.
What is SPRB's revenue and growth?
Spruce Biosciences, Inc.. reported revenue of $0.0.
Does SPRB pay dividends?
Spruce Biosciences, Inc.. does not currently pay dividends.
Where can I find SPRB SEC filings?
Official SEC filings for Spruce Biosciences, Inc.. (CIK: 0001683553) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SPRB's EPS?
Spruce Biosciences, Inc.. has a diluted EPS of $-8.94.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SPRB's fundamental grade?
Based on our AI fundamental analysis in May 2026, Spruce Biosciences, Inc.. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SPRB stock overvalued or undervalued?
Valuation metrics for SPRB: ROE of -35.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SPRB's AI grade for 2026?
Our dual AI analysis gives Spruce Biosciences, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SPRB's free cash flow?
Spruce Biosciences, Inc..'s operating cash flow is $-8.7M, with capital expenditures of $10.0K.
How does SPRB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -35.4% (avg: 15%), current ratio 4.67 (avg: 2).